PMID- 22212411
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20211021
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 33
IP  - 7
DP  - 2013 Jul
TI  - Immunohistological analysis of synovium treated with abatacept in rheumatoid 
      arthritis.
PG  - 1883-7
LID - 10.1007/s00296-011-2326-8 [doi]
AB  - The aim of this study was to investigate the histological changes following the 
      treatment with abatacept compared with methotrexate (MTX) by an 
      immunohistological examination of synovial tissue for eleven different molecules 
      to detect the expression patterns of cytokines. We histologically assessed the 
      synovial tissues from 10 methotrexate (MTX)-treated RA patients as controls and 5 
      abatacept plus MTX-treated RA patients. The synovium samples from both group were 
      assessed by hematoxylin and eosin (HE) staining and analyzed for their expression 
      of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), matrix 
      metalloproteinase-3 (MMP-3), CD20, CD68, vascular endothelial growth factor 
      (VEGF), CD4, CD8, CD28, CD80, and CD86 by an immunohistological examination. HE 
      staining showed that there was a decrease in cell proliferation in the synovium 
      of the RA patients who received abatacept compared with the controls. TNF-alpha, 
      IL-6, and VEGF were not significantly different in either of the groups. On the 
      other hand, MMP-3, CD68, CD4, CD8, CD20, CD80, and CD86 were significantly 
      decreased in the abatacept group compared with the control (P < 0.05). Based on 
      the histological analysis of the synovium, it appears that the efficacy of the 
      treatment with abatacept may involve the inhibition of cell proliferation, with 
      decreases in the expression of MMP-3, CD68, CD4, CD8, CD20, CD80, and CD86 in the 
      synovium. These findings indicate inhibition of not only T cells but also B cells 
      and macrophages, which likely plays a role in the efficacy of abatacept in RA 
      patients.
FAU - Kanbe, Katsuaki
AU  - Kanbe K
AD  - Department of Orthopaedic Surgery, Tokyo Women's Medical University, Medical 
      Center East, 2-1-10 Nishiogu, Arakawa, Tokyo 116-8567, Japan. 
      kanbeor@dnh.twmu.ac.jp
FAU - Chiba, Junji
AU  - Chiba J
FAU - Nakamura, Atsushi
AU  - Nakamura A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20120103
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Immunoconjugates)
RN  - 0 (Inflammation Mediators)
RN  - 7D0YB67S97 (Abatacept)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Abatacept
MH  - Aged
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy/immunology
MH  - B-Lymphocytes/drug effects/immunology
MH  - Biomarkers/metabolism
MH  - Case-Control Studies
MH  - Cell Proliferation/drug effects
MH  - Female
MH  - Humans
MH  - Immunoconjugates/*therapeutic use
MH  - *Immunohistochemistry
MH  - Inflammation Mediators/*metabolism
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Synovial Membrane/*drug effects/immunology/pathology
MH  - T-Lymphocytes/drug effects/immunology
MH  - Treatment Outcome
EDAT- 2012/01/04 06:00
MHDA- 2014/01/31 06:00
CRDT- 2012/01/04 06:00
PHST- 2011/09/07 00:00 [received]
PHST- 2011/12/10 00:00 [accepted]
PHST- 2012/01/04 06:00 [entrez]
PHST- 2012/01/04 06:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - 10.1007/s00296-011-2326-8 [doi]
PST - ppublish
SO  - Rheumatol Int. 2013 Jul;33(7):1883-7. doi: 10.1007/s00296-011-2326-8. Epub 2012 
      Jan 3.